抄録：The adoptive transfer of T cells engineered with tumor-specific T cell receptors (TCRs) can effectively mobilize the immune system against cancer. In our group, we focus on neoantigen-specific T cell therapies that are personalized in its truest sense because suitable neoantigen targets and specific TCRs have to be identified for each patient individually. We make use of syngeneic animal models to develop mutation-specific T cell therapies that are designed to eradicate established cancer and thus prevent relapse. By treating primary cancers, we test different combination therapies necessary to overcome relapse often caused by the antigenic heterogeneity of established tumors. In order to shape clinical implementation, we use an HLA-A2-transgenic cancer model that facilitates the evaluation of TCR and antigen quality and thus the characterization of key parameters that determine therapeutic success. In my talk I will provide a brief overview about our projects and present current data.